TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$400 Million

Theravance Biopharma

Sole Placement Agent, February 2020

Theravance Biopharma
Fixed Rate Term Notes

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development, and commercialization of organ-selective medicines. The Company’s focus areas for research are inflammation and immunology.

More Like This

Mar 2024

Exchange of all Outstanding Series B Convertible Preferred Stock for Common Stock

Financial Advisor

View Details >
Mar 2024
$600 Million

Follow-on Offering

Bookrunner

View Details >
Mar 2024
$150 Million

Underwritten Offering

Lead Left Bookrunner

View Details >